Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Classification of Clinical Sub-types of Mild Cognitive Impairment with Neuroimaging Biomarkers for Alzheimer’s Disease and Cerebrovascular Disease
EF 2013-14
Résumé
According to the World Health Organization, 35.6 million people worldwide are currently living with dementia; primarily due to an aging population, this figure is expected to double by 2030. The two primary causes of dementia are Alzheimer’s disease and vascular dementia, which are characterized by different but potentially interacting etiologies. Alzheimer’s disease is characterized by the accumulation of plaques composed of í-amyloid peptides in the brain. Vascular dementia is caused by disruption of normal blood flow to different regions of the brain, resulting in irreversible tissue damage. The focus of the project is to examine the intermediate stage between healthy aging and dementia, known as mild cognitive impairment.
Mild cognitive impairment can be classified into two clinical sub-types, amnestic and non-amnestic. The amnestic sub-type refers to cognitive impairment involving memory deficits, whereas the non-amnestic sub-type classifies the presence of other cognitive dysfunctions. Recent studies have suggested that these different clinical sub-types of mild cognitive impairment have different likelihoods of progression to specific types of dementia. For example, patients with amnestic mild cognitive impairment have an increased likelihood of progression to Alzheimer’s disease. Thus, this project will characterize patterns of altered brain structure and function in amnestic and non-amnestic mild cognitive impairment in order to identify prodromal neuroimaging biomarkers that better differentiate progression to Alzheimer’s disease or vascular dementia.
In this project, we will use established neuropsychological testing to assess neurocognitive functions, and utilize structural and functional neuroimaging with positron emission tomography (PET) and magnetic resonance (MR) imaging. First, PET imaging with Pittsburgh Compound-B (PiB) has been used as a novel diagnostic tool for Alzheimer’s disease for over a decade. PiB is selective for í-amyloid peptides. Thus, regions of hyperintensity on PET PIB images indicate areas of increased í-amyloid concentration. Second, white matter lesions (WML), commonly associated with vascular dementia, are easily identified as hyperintensities on conventional T2-weighted MR images. Third, arterial spin labeling is a non-invasive MR technique for measuring quantitative blood flow. In addition to structural changes, we will also examine the differences in cerebral perfusion patterns between amnestic and non-amnestic mild cognitive impairment. We hypothesize that we will be able to classify the prodromal sub-types of mild cognitive impairment based on these neuroimaging biomarkers and neuropsychological testing.
Ultimately, characterizing the prodromal stages of dementia based on PIB PET, presence of white matter lesions, and alterations of cerebral perfusion will lead to better diagnoses of mild cognitive impairment. In this project, we will be examining these factors longitudinally over two years to better understand prognosis for dementia. The ultimate goal of this research is to characterize clinical outcomes of the intermediate stages between healthy cognitive function and dementia. The Alzheimer Society of Canada estimates the total economic burden to be $153 billion by 2038; thus, better understanding may lead to approaches that will reduce the health and economic burden of cognitive disorders.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311851
Name
Wang Xinjue Rachel
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Classification of Clinical Sub-types of Mild Cognitive Impairment with Neuroimaging Biomarkers for Alzheimer’s Disease and Cerebrovascular Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer’S Disease; Amnestic Mild Cognitive Impairment; Arterial Spin Labeling Perfusion; Magnetic Resonance Imaging; Neurocognitive Assessment; Non-Amnestic Mild Cognitive Impairment; Positron Emission Tomography; T2-Weighted Imaging; Vascular Dementia; White Matter Lesions
Abstract
According to the World Health Organization, 35.6 million people worldwide are currently living with dementia; primarily due to an aging population, this figure is expected to double by 2030. The two primary causes of dementia are Alzheimer’s disease and vascular dementia, which are characterized by different but potentially interacting etiologies. Alzheimer’s disease is characterized by the accumulation of plaques composed of í-amyloid peptides in the brain. Vascular dementia is caused by disruption of normal blood flow to different regions of the brain, resulting in irreversible tissue damage. The focus of the project is to examine the intermediate stage between healthy aging and dementia, known as mild cognitive impairment.
Mild cognitive impairment can be classified into two clinical sub-types, amnestic and non-amnestic. The amnestic sub-type refers to cognitive impairment involving memory deficits, whereas the non-amnestic sub-type classifies the presence of other cognitive dysfunctions. Recent studies have suggested that these different clinical sub-types of mild cognitive impairment have different likelihoods of progression to specific types of dementia. For example, patients with amnestic mild cognitive impairment have an increased likelihood of progression to Alzheimer’s disease. Thus, this project will characterize patterns of altered brain structure and function in amnestic and non-amnestic mild cognitive impairment in order to identify prodromal neuroimaging biomarkers that better differentiate progression to Alzheimer’s disease or vascular dementia.
In this project, we will use established neuropsychological testing to assess neurocognitive functions, and utilize structural and functional neuroimaging with positron emission tomography (PET) and magnetic resonance (MR) imaging. First, PET imaging with Pittsburgh Compound-B (PiB) has been used as a novel diagnostic tool for Alzheimer’s disease for over a decade. PiB is selective for í-amyloid peptides. Thus, regions of hyperintensity on PET PIB images indicate areas of increased í-amyloid concentration. Second, white matter lesions (WML), commonly associated with vascular dementia, are easily identified as hyperintensities on conventional T2-weighted MR images. Third, arterial spin labeling is a non-invasive MR technique for measuring quantitative blood flow. In addition to structural changes, we will also examine the differences in cerebral perfusion patterns between amnestic and non-amnestic mild cognitive impairment. We hypothesize that we will be able to classify the prodromal sub-types of mild cognitive impairment based on these neuroimaging biomarkers and neuropsychological testing.
Ultimately, characterizing the prodromal stages of dementia based on PIB PET, presence of white matter lesions, and alterations of cerebral perfusion will lead to better diagnoses of mild cognitive impairment. In this project, we will be examining these factors longitudinally over two years to better understand prognosis for dementia. The ultimate goal of this research is to characterize clinical outcomes of the intermediate stages between healthy cognitive function and dementia. The Alzheimer Society of Canada estimates the total economic burden to be $153 billion by 2038; thus, better understanding may lead to approaches that will reduce the health and economic burden of cognitive disorders.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Xinjue Rachel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~